FAQ: Cybin Inc. CEO Transition and Company Overview

What is the main announcement regarding Cybin Inc.’s leadership?

Cybin Inc. announced that Doug Drysdale stepped down as Chief Executive Officer effective September 2, 2025, and was succeeded on an interim basis by Co-Founder and President Eric So.

Who is the new interim CEO and what is their background with the company?

Eric So, who is a co-founder and President of Cybin, has been appointed as the interim CEO. He will focus on advancing Cybin’s clinical pipeline including CYB003 and CYB004 during the transition.

When did this leadership change take effect?

The leadership change took effect on September 2, 2025, when Doug Drysdale stepped down as CEO and Eric So assumed the interim CEO role.

What is the Board of Directors doing to find a permanent CEO?

The Board of Directors has formed a committee to conduct a search for a new CEO to lead the company through commercialization while Eric So focuses on the clinical pipeline during the transition.

What are CYB003 and CYB004 that Eric So will be focusing on?

CYB003 is a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004 is a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder.

What regulatory designation has CYB003 received?

CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for its development as an adjunctive treatment for major depressive disorder.

Where is Cybin Inc. operational?

Cybin is operational in Canada, the United States, the United Kingdom, and Ireland, having been founded in 2019.

Where can investors find the latest news and updates about Cybin?

The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

What is Cybin Inc.’s overall mission and focus?

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.